|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Are There Predictors for Successful Treatment of Oligometastatic Prostate Cancer? APCCC 2022 Presentation
|
|
Piet Ost, MD
|
| At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Piet Ost presents predictors for the successful treatment of patients with oligometastatic and oligoprogressive prostate cancer,
|
|
|
|
|
|
|
|
|
|
|
|
|
What is the Evidence of MDT in Synchronous vs Metachronous mHSPC? APCCC 2022 Presentation
|
|
Daniel Spratt, MD
|
| At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt presents the evidence for metastasis directed therapy (MDT) in patients with synchronous and metachronous metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
|
|
|
|
|
|
|
|
|
|
|
Does “Oligoprogressive” Prostate Cancer Exist as a Distinct Clinically Meaningful Entity and if Yes, How To Treat It? APCCC 2022 Presentation
|
|
Robert Jones, MD
|
| At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Robert Jones presents on the treatment of patients with oligometastatic and oligoprogressive prostate cancer, focusing on whether “oligoprogressive” prostate cancer exists as a distinct clinical entity.
|
|
|
|
|
|
|
|
|
|
|
|
| Metastasis-Directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer A UroToday Journal Club |
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen provide insights into the European Urology publication titled "Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis" in this UroToday Journal Club. |
|
|
|
|
|
|
|
|
|
|
| Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials |
| Matthew Deek, MD |
| Mathew Deek discusses a pooled analysis of the STOMP and ORIOLE trials examining long-term outcomes and genetic predictors of response to metastasis directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer and assess the ability of a high-risk (HiRi) mutational signature to provide prognostic and predictive information regarding MDT response. |
|
|
|
|
|
| Local and Focal: What’s Next in Salvage Therapy? - Discussion
|
| Mark Garzotto, MD
|
| Mark Garzotto provides a discussion of salvage therapies in patients with prostate cancer. Short-term enzalutamide improved biochemical recurrence with a favourable toxicity profile. However, clinically meaningful endpoints remain to be assessed. Given the recently demonstrated benefit of novel hormonal therapies in the non-metastatic castration sensitive space along with primary radiotherapy for high-risk disease, these data suggest that treatment intensification may have a role earlier in the disease process.
|
|
|
|
|
|
| Optimizing Therapy for Locally Advanced Prostate Cancer |
| Brian Chapin, MD |
| Brian Chapin discusses optimizing therapy for locally advanced prostate cancer. Dr. Chapin highlights that the disease states of prostate cancer have become quite detailed, based on castration status and line of therapy received. However, particularly in the locally advanced setting commonly leading to disease recurrence, is it possible to alter the disease course with an intervention? Is it possible to cure these patients? Prolong survival? Delay time to systemic therapy? |
|
|
|
|
|
|
|
|
|
|
| State-of-the-Art Lecture: PSMA Diagnostics and Theranostics |
| William J. Aronson, MD |
| In a podium presentation at the Friday morning plenary of the 2022 American Urologic Association Annual Meeting held in New Orleans and virtually, William Aronson presented a State-of-the-Art Lecture on prostate specific membrane antigen (PSMA) Diagnostics and Theranostics. Dr. Aronson highlighted that PSMA-PET has redefined patterns of prostate cancer spread resulting in profound transformation of prostate cancer management. |
|
|
|
|
|
| Recurrent Prostate Cancer: Treatment Landscape of Hormone Sensitive Recurring M1 Prostate Cancer |
| Ursula M. Vogl, MD, MBA |
| Ursula Vogl discusses the treatment landscape of hormone sensitive recurrent M1 prostate cancer. Recurring M1 hormone-sensitive prostate cancer mostly presents with low-volume disease, but modern-imaging will diagnose more metachronous high-volume disease in the future. High-level evidence exists for systemic treatment for metachronous low-volume and high-volume mHSPC (ADT plus: apalutamide, enzalutamide, docetaxel, docetaxel + darolutamide). |
|
|
|
|
|
The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited - Beyond the Abstract
|
| Matthew Deek, MD |
| Metastasis has long been viewed as part of a binary state, not only in terms of diagnosis but also in treatment decisions. However, this prevailing view of metastasis has been challenged and emerging evidence suggests metastatic disease is instead better described as a spectrum of metastatic proclivity currently represented clinically by enumeration of lesions. The spectrum theory postulates the existence of a low volume metastatic state, termed oligometastasis, where individuals with a limited number of lesions, typically five or less, have disease that biologically acts more in a locoregional fashion rather than extensive systemic metastasis. |
|
|
|
|
|
| Debate: Imaging Directed Treatment for BCR
|
| Nicholas D. James, BSc, MBBS, PhD, FRCP, FRCR |
| The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on biochemical recurrence, and a presentation by Nicholas James discussing imaging directed treatment for biochemical recurrence. |
|
|
|
|
|
| What is the Evidence of MDT in Synchronous vs Metachronous mHSPC? |
| Daniel Spratt, MD |
| Daniel Spratt discusses the evidence for metastasis directed therapy (MDT) in patients with synchronous and metachronous metastatic hormone sensitive prostate cancer (mHSPC). In terms of level-setting, he began by highlighting the landscape of oligometastatic cancer, with a focus on the top right corner (synchronous oligometastatic disease, metachronous oligorecurrent or oligoprogressive disease). |
|
|
|
|
|
|
